清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial

阿德福韦 恩替卡韦 医学 内科学 胃肠病学 乙型肝炎表面抗原 拉米夫定 联合疗法 HBeAg 人口 乙型肝炎病毒 乙型肝炎 病毒学 病毒 环境卫生
作者
Young Suk Lim,Geum Youn Gwak,Jonggi Choi,Yung Sang Lee,Kwan Soo Byun,Yoon Jun Kim,Byung Chul Yoo,So Young Kwon,Han Chu Lee
出处
期刊:Journal of Hepatology [Elsevier BV]
卷期号:71 (1): 35-44 被引量:30
标识
DOI:10.1016/j.jhep.2019.02.021
摘要

•240 weeks of TDF monotherapy provided an increasing virologic response rate in patients with multidrug-resistant HBV. •Virologic breakthrough was rare and not associated with emergence of additional resistance mutations. •The HBeAg seroconversion rate was very low and no patient achieved HBsAg seroclearance up to week 240. •Prolonged continuous treatment may be needed to maintain viral suppression in these patients. •Progressive and significant decreases in renal function and bone mineral density after week 144 raise safety concerns. Background & Aims Tenofovir disoproxil fumarate (TDF) monotherapy has displayed non-inferior efficacy to TDF plus entecavir (ETV) combination therapy in patients with hepatitis B virus (HBV) resistant to ETV and/or adefovir (ADV). Nonetheless, the virologic response rate was suboptimal in patients receiving up to 144 weeks of TDF monotherapy. We aimed to assess the efficacy and safety of TDF monotherapy given for up to 240 weeks. Methods One trial enrolled patients with ETV resistance without ADV resistance (n = 90), and another trial included patients with ADV resistance (n = 102). Most patients (91.2%) also had lamivudine resistance. Patients were randomized 1:1 to receive TDF monotherapy or TDF + ETV combination therapy for 48 weeks, and then TDF monotherapy until week 240. We compared efficacy between the studies and safety in the pooled population at 240 weeks. Results At week 240, the proportion of patients with serum HBV DNA <15 IU/ml was not significantly different between the ETV and ADV resistance groups in the full analysis set (84.4% vs. 73.5%; p = 0.07), which was significantly different by on-treatment analysis (92.7% vs. 79.8%; p = 0.02). Virologic blips associated with poor medication adherence occurred in 7 patients throughout the 240 weeks. None developed additional HBV resistance mutations. Among the 170 HBV e antigen (HBeAg)-positive patients at baseline, 12 (7.1%) achieved HBeAg seroconversion at week 240. None achieved HBV surface antigen seroclearance. Significant decreases from baseline were observed at week 240 in the estimated glomerular filtration rate (−3.21 ml/min/1.73 m2 by the CKD-EPI equation, p <0.001) and bone mineral density (g/cm2) at the femur (−2.48%, p <0.001). Conclusions Up to 240 weeks of TDF monotherapy provided an increasing virologic response rate in heavily pretreated patients with HBV resistant to ETV and/or ADV. However, it was associated with poor serological responses and decreasing renal function and bone mineral density. (ClinicalTrials.gov No, NCT01639066 and NCT01639092). Lay summary In patients chronically infected with hepatitis B virus resistant to multiple drugs including lamivudine, entecavir, and/or adefovir, tenofovir disoproxil fumarate (TDF) monotherapy showed non-inferior efficacy compared with the combination therapy of TDF plus entecavir. Nonetheless, short-term TDF monotherapy was associated with suboptimal virologic response, and its long-term safety was uncertain. This study displayed that 240 weeks of TDF monotherapy provided a virologic response in most of those patients, but it was associated with poor serological responses and decreasing renal function and bone mineral density. Tenofovir disoproxil fumarate (TDF) monotherapy has displayed non-inferior efficacy to TDF plus entecavir (ETV) combination therapy in patients with hepatitis B virus (HBV) resistant to ETV and/or adefovir (ADV). Nonetheless, the virologic response rate was suboptimal in patients receiving up to 144 weeks of TDF monotherapy. We aimed to assess the efficacy and safety of TDF monotherapy given for up to 240 weeks. One trial enrolled patients with ETV resistance without ADV resistance (n = 90), and another trial included patients with ADV resistance (n = 102). Most patients (91.2%) also had lamivudine resistance. Patients were randomized 1:1 to receive TDF monotherapy or TDF + ETV combination therapy for 48 weeks, and then TDF monotherapy until week 240. We compared efficacy between the studies and safety in the pooled population at 240 weeks. At week 240, the proportion of patients with serum HBV DNA <15 IU/ml was not significantly different between the ETV and ADV resistance groups in the full analysis set (84.4% vs. 73.5%; p = 0.07), which was significantly different by on-treatment analysis (92.7% vs. 79.8%; p = 0.02). Virologic blips associated with poor medication adherence occurred in 7 patients throughout the 240 weeks. None developed additional HBV resistance mutations. Among the 170 HBV e antigen (HBeAg)-positive patients at baseline, 12 (7.1%) achieved HBeAg seroconversion at week 240. None achieved HBV surface antigen seroclearance. Significant decreases from baseline were observed at week 240 in the estimated glomerular filtration rate (−3.21 ml/min/1.73 m2 by the CKD-EPI equation, p <0.001) and bone mineral density (g/cm2) at the femur (−2.48%, p <0.001). Up to 240 weeks of TDF monotherapy provided an increasing virologic response rate in heavily pretreated patients with HBV resistant to ETV and/or ADV. However, it was associated with poor serological responses and decreasing renal function and bone mineral density.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
番茄酱完成签到 ,获得积分10
14秒前
ycyang完成签到,获得积分20
19秒前
阿尔法贝塔完成签到 ,获得积分10
27秒前
28秒前
lhn完成签到 ,获得积分10
31秒前
坚定向彤发布了新的文献求助50
33秒前
华理附院孙文博完成签到 ,获得积分10
35秒前
隐形曼青应助科研通管家采纳,获得10
38秒前
Bryan应助科研通管家采纳,获得10
38秒前
Bryan应助科研通管家采纳,获得10
38秒前
Bryan应助科研通管家采纳,获得10
38秒前
Bryan应助科研通管家采纳,获得10
38秒前
居里姐姐完成签到 ,获得积分10
47秒前
niko完成签到 ,获得积分10
49秒前
我和你完成签到 ,获得积分10
54秒前
sowhat完成签到 ,获得积分10
59秒前
大猪完成签到 ,获得积分10
1分钟前
威武灵阳完成签到,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
MrChew完成签到 ,获得积分10
1分钟前
涛1完成签到 ,获得积分10
1分钟前
guhao完成签到 ,获得积分10
1分钟前
zx完成签到 ,获得积分10
1分钟前
知行者完成签到 ,获得积分10
1分钟前
arsenal完成签到 ,获得积分10
1分钟前
中恐完成签到,获得积分0
2分钟前
hyxu678完成签到,获得积分10
2分钟前
calphen完成签到 ,获得积分10
2分钟前
916应助lixian采纳,获得10
2分钟前
长情箴完成签到 ,获得积分10
2分钟前
mark33442完成签到,获得积分10
2分钟前
热心的飞风完成签到 ,获得积分10
2分钟前
荆华完成签到,获得积分10
2分钟前
树苗白菜钱完成签到,获得积分10
2分钟前
2分钟前
D-L@rabbit完成签到 ,获得积分10
2分钟前
兴奋的小笼包完成签到,获得积分10
2分钟前
土豆晴完成签到 ,获得积分10
2分钟前
jibenkun完成签到,获得积分10
2分钟前
量子星尘发布了新的文献求助10
2分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976735
求助须知:如何正确求助?哪些是违规求助? 3520831
关于积分的说明 11204848
捐赠科研通 3257602
什么是DOI,文献DOI怎么找? 1798800
邀请新用户注册赠送积分活动 877897
科研通“疑难数据库(出版商)”最低求助积分说明 806648